PER-114-12未知未知
EFFICACY, PHARMACOKINETICS (PK), AND SAFETY OF BI 695500 VERSUS RITUXIMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS (RA): A RANDOMIZED, DOUBLE-BLIND, PARALLEL ARM, MULTIPLE DOSE, ACTIVE COMPARATOR TRIAL.
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 80（—）
入选标准
- •1. MUST GIVE WRITTEN INFORMED CONSENT AND BE WILLING TO FOLLOW THE PROTOCOL
- •2. MALE OR FEMALE PARTICIPANTS, BETWEEN 18 AND 80 YEARS OF AGE, WHO HAVE A DIAGNOSIS OF MODERATELY TO SEVERELY ACTIVE RA FOR AT LEAST 6 MONTHS AS DEFINED BY AT LEAST SIX SWOLLEN JOINTS (66 JOINT COUNT) AND AT LEAST EIGHT TENDER JOINTS (68 JOINT COUNT) AT SCREENING AND BASELINE (DAY 1), AND EITHER AN ERYTHROCYTE SEDIMENTATION RATE (ESR) OF >28 MM/HOUR OR A CRP LEVEL >1.0 MG/DL (NORMAL: < 0.4 MG/DL) AT SCREENING. PATIENTS MUST HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO CONVENTIONAL DMARD THERAPY INCLUDING AT LEAST ONE TNF INHIBITOR
- •3. POSITIVE FOR RF AND/OR ANTI-CCP ANTIBODIES.
- •4. CURRENT TREATMENT FOR RA ON AN OUTPATIENT BASIS:
- •(A) MUST BE CURRENTLY RECEIVING AND TOLERATING ORAL OR PARENTERAL MTX THERAPY AT A DOSE OF 15-25 MG PER WEEK (DOSE MAY BE AS LOW AS 10 MG PER WEEK IF THE PATIENT IS UNABLE TO TOLERATE A HIGHER DOSE) FOR AT LEAST 12 WEEKS IMMEDIATELY PRIOR TO DAY 1. THE DOSE SHOULD BE STABLE FOR AT LEAST 4 WEEKS PRIOR TO DAY 1 UNTIL WEEK 24. AFTER WEEK 24 THE ADMINISTRATION ROUTE CAN BE CHANGED AT THE INVESTIGATOR´S DISCRETION.
- •(B) PATIENTS MUST BE WILLING TO RECEIVE ORAL FOLIC ACID (AT LEAST 5 MG/WEEK OR AS PER LOCAL PRACTICE) OR EQUIVALENT DURING THE ENTIRE STUDY (MANDATORY CO-MEDICATION FOR MTX TREATMENT).
- •(c) BIOLOGIC AGENTS AND DMARDS (OTHER THAN MTX) MUST BE WITHDRAWN AT LEAST 2 WEEKS PRIOR TO DAY 1, EXCEPT AZATHIOPRINE WHICH MUST BE WITHDRAWN AT LEAST 4 WEEKS PRIOR TO DAY 1
排除标准
- •1. ACR FUNCTIONAL CLASS IV (SEE APPENDIX 10.1) OR WHEELCHAIR/BED-BOUND.
- •2. PRIMARY OR SECONDARY IMMUNODEFICIENCY (HISTORY OF, OR CURRENTLY ACTIVE), INCLUDING
- •KNOWN HISTORY OF HUMAN IMMUNODEFICIENCY VIRUS INFECTION.
- •3. HISTORY OF POSITIVE PURIFIED PROTEIN DERIVATIVE TEST (POSITIVE TUBERCULOSIS [TB] TEST)
- •WITHOUT TREATMENT FOR TB INFECTION OR CHEMOPROPHYLAXIS FOR TB EXPOSURE.
- •4. KNOWN CORONARY ARTERY DISEASE OR SIGNIFICANT CARDIAC ARRHYTHMIAS OR SEVERE CONGESTIVE HEART FAILURE (NEW YORK HEART ASSOCIATION CLASSES III OR IV), OR INTERSTITIAL LUNG DISEASE OBSERVED ON CHEST X-RAY.
- •5. HISTORY OF IGE-MEDIATED OR NON-IGE-MEDIATED HYPERSENSITIVITY OR KNOWN ANAPHYLAXIS TO MOUSE PROTEINS OR A HISTORY OF HYPERSENSITIVITY TO ANTIBODY THERAPY.
- •6. HISTORY OF CANCER INCLUDING SOLID TUMORS, HEMATOLOGIC MALIGNANCIES, AND CARCINOMA SITU (EXCEPT PARTICIPANTS WITH PREVIOUS RESECTED AND CURED BASAL OR SQUAMOUS CELL CARCINOMA, TREATED CERVICAL DYSPLASIA, OR TREATED IN SITU GRADE I CERVICAL CANCER WITHIN 5 YEARS PRIOR TO THE SCREENING VISIT).
- •7. HISTORY OF INFLAMED PANCREAS OR CURRENT PEPTIC ULCER DISEASE.
- •8. RECEIPT OF A LIVE/ATTENUATED VACCINE WITHIN 12 WEEKS PRIOR TO THE SCREENING VISIT.
研究者
相似试验
已完成
不适用
Clinical efficacy, saftey and pharmacodynamics of antifungal agents on chronic pulmonary mycosisJPRN-UMIN000003108ational Hospital Organization, Tokyo National Hospital20
招募中
1 期
Clinical evaluation of the efficacy of purified bioactive peptides from Spirulina Platensis algae on the healing of wounds after periodontal flap surgery (double-blinded randomized clinical trial)IRCT20221021056257N1Tabriz University of Medical Sciences30
招募中
不适用
Robot-assisted rehabilitation of gait and functional improvement for knee surgery patientsDiseases of the musculo-skeletal system and connective tissueKCT0002615lsan Univeristy Hospital60
进行中（未招募）
不适用
To determine the safety, effectiveness, and effect on the body of GreenGene F in previously treated patients 12 years of age or older who have severe Hemophilia A.Haemophilia AMedDRA version: 17.0Level: LLTClassification code 10018937Term: Haemophilia ASystem Organ Class: 100000004850EUCTR2012-001445-40-PLGreen Cross Corporation124
进行中（未招募）
不适用
To determine the safety, effectiveness, and effect on the body of GreenGene F in previously treated patients 12 years of age or older who have severe Hemophilia A.MedDRA version: 17.0Level: LLTClassification code 10060613Term: Hemophilia A (Factor VIII)System Organ Class: 100000004850Hemophilia AEUCTR2012-001445-40-HRGreen Cross Corporation124